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Case
We report on a 32-year-old patient with reﬂux
nephropathy diagnosed at the age of 11 years. Over
the following 18 years, he developed end-stage renal
disease (ESRD) and was started on haemodialysis in
2001. He had to be treated for severe hypertension with
various medications including diuretics, b-blockers,
a-blockers, calcium antagonists and angiotensin recep-
tor blockers in various combinations. After 1 year of
haemodialysis, the patient received a cadaveric renal
transplant that immediately functioned well. Immuno-
suppression was installed according to the local
standard protocol with basiliximab, cyclosporin A,
mycophenolate mofetil and corticosteroids. The patient
suffered from one episode of biopsy-proven acute
tubulointerstitial rejection in the ﬁrst week after
transplantation, which was treated with three pulses
of intravenous methylprednisolone. The subsequent
course was uneventful, and corticosteroids could be
stopped after 9 months.
The patient’s family history revealed hypertension
in his father and mother. The father suffered from a
myocardial infarction at the age of 60, when hyperten-
sion was detected and treated. The mother has
acknowledged mild to moderate hypertension for >10
years, but she was never treated and no further
cardiovascular evaluation was performed.
Pulse and blood pressure profiles
Already during haemodialysis this young and well-
trained male patient suffered from moderate to severe
hypertension. This problem persisted after trans-
plantation and was always associated with high normal
to high resting heart rate (80–115/min). Therefore,
post-transplant antihypertensive treatment was based
primarily on b-blockers. The course of resting blood
pressure and heart rate under escalating doses of
atenolol is shown in Figure 1. Since atenolol had no
effect on both parameters even at 200mg/day, it
subsequently was replaced by carvedilol. This drug’s
combined a- and b-blocking effect led to an immediate
amelioration of blood pressure. However, although the
dose was maximally escalated, the patient’s heart rate
remained 100/min (Figure 1).
Therefore, secondary causes of tachycardia were
sought. Haemoglobin, thyrotropic hormone, fasting
cortisol and glucose were within normal ranges.
Cardiological examination revealed sinus tachycardia
on resting electrocardiogram (ECG) and left ventric-
ular hypertrophy in echocardiography, but no other
abnormalities.
Based on pathophysiological considerations, the
combination of tachycardia, hypertension and a clinical
resistance to high dose b-blocker therapy pointed to a
gain of function of the b1 adrenergic receptor. This
hypothesis was evaluated in two respects: (i) a genetic
analysis of the two most frequent polymorphisms of the
b1 adrenergic receptor was performed (see below); and
(ii) clinically: diltiazem, a class II Ca channel blocker
with inhibitory effects on atrioventricular conduction
independent of b1 adrenergic receptors, was added to
the otherwise unchanged drug therapy (Figure 1). This
efﬁciently lowered the patient’s resting heart rate as
measured by 24 h ECG analysis before and after
introduction of diltiazem (mean pulse drop of 20/min).
Correspondence and offprint requests to: Thomas Fehr, MD,
Transplantation Biology Research Center, Massachusetts General
Hospital, MGH East CNY 149 5th ﬂoor, 13th street, Boston MA
02129, USA. Email: thomas.fehr@tbrc.mgh.harvard.edu
 2004 European Renal Association–European Dialysis and Transplant Association
Molecular analysis of two 1 adrenergic receptor
polymorphisms
In 1999, two important b1 adrenergic receptor poly-
morphisms were identiﬁed: one at amino acid position
49 (Ser49Gly) and one at position 389 (Arg389Gly) [1].
Whereas homozygosity for the serine allele at position
49 is associated with higher resting heart rate [2],
homozygosity for arginine at position 389 is linked to
elevated blood pressure and elevated heart rate [3].
Therefore, we analysed these two polymorphisms in
our patient and his parents according to the original
description in 1999 [1] with modiﬁed primers. Brieﬂy,
genomic DNA was extracted from EDTA blood. The
polymorphic loci were ampliﬁed by polymerase chain
reaction (PCR) with the following primers: for the
Ser49Gly locus, upstream 50-GTCGCCGCCCGCCT
CGTT-30 and downstream 50-CCATGCCCGCTGTC
CACTGCT-30; and for the Arg389Gly locus, upstream
50-GGCCTTCAACCCCATCATCTA-30 and down-
stream 50-CCGGTCTCCGTGGGTCGCGT-30 [2].
The conditions for the PCRs were as follows: initial
denaturation at 94C for 5min, 40 cycles with 1min at
94C, 1min at 68C (Ser49Gly) or 63C (Arg389Gly)
and 2min at 72C with ﬁnal extension for 10min.
The PCR products were then directly sequenced, and
the results are shown in Figure 2. The ﬁgure shows
electropherograms from an automated sequence
analyser, where each of the four bases (A, T, C and G)
is represented by an individual colour. In Figure 2A,
nucleic acid position 145 is shaded. The electrophero-
gram shows a single green peak for A in all three
individuals, meaning that they are all homozygous for
A at this position. The triplet AGC codes for the amino
acid serine at position 49 (Ser49Gly locus). In Figure
2B, the nucleic acid position 1165 is shaded. In our
index patient and his mother, we observed a single peak
for C, meaning that they are homozygous for C at this
position. However, the father shows a double peak
for C (blue, lower peak) and G (black, higher peak).
This means that he is heterozygous at this position. The
triplet CGA codes for the amino acid arginine at
position 389 (Arg389Gly locus), whereas for the father
the triplet GGA codes for glycine on one and CGA for
arginine on the other allele.
Thus, our patient and his mother were both homo-
zygous for serine at position 49 and for arginine at
position 389, therefore harbouring the highest risk
constellation for tachycardia and hypertension at
these two loci. In contrast, the patient’s father was
heterozygous for arginine at position 389, but also
homozygous for serine at 49.
Discussion
Cardiovascular diseases are the most frequent cause of
hospitalizations and death in industrialized countries.
Several modiﬁable risk factors such as hypertension,
Fig. 1. Heart rate (HR) and systolic blood pressure (SBP) course. Heart rate (circles) and systolic blood pressure (diamonds) are indicated for
the ﬁrst year after renal transplantation. Medications with an effect on blood pressure and/or heart rate (name and total daily dose) are
mentioned in separate boxes: atenolol is a b1-selective b-blocker, carvedilol a combined b- and a-blocker, amlodipin a class I calcium channel
blocker and diltiazem a class II calcium channel blocker with inhibitory effects on atrioventricular conduction.
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hyperlipidaemia, diabetes mellitus and smoking have
been identiﬁed. Familial history of coronary heart
disease or stroke is another important risk factor,
which until now could not be modiﬁed. In the era of
molecular medicine, several genetic causes of cardio-
vascular diseases have been recognized. Some of them
inﬂuence the mentioned cardiovascular risk factors,
e.g. mutations of the low-density lipoprotein receptor,
genetic variants of diabetes mellitus (maturity onset
diabetes of the young type 1–6) and angiotensin-
converting enzyme (ACE) polymorphisms predisposing
to hypertension [4]. Others lead directly to structural
(e.g. genetic forms of hypertrophic and dilated cardi-
omyopathy with myosin or troponin mutations) or
arrhythmogenic heart disease (e.g. familial forms of
long-QT syndrome with ion channel mutations) [5].
In recent years, reports on adrenergic receptor poly-
morphisms (a1, b1, b2, b3) and their inﬂuence on
blood pressure, heart rate and prognosis of cardio-
vascular disease have been published. The human b1
adrenergic receptor was cloned in 1987 [6], but the
signiﬁcance of polymorphisms in this gene for the
course of cardiovascular disease was recognized only
10 years later. The two main polymorphisms of the
b1 adrenergic receptor (Ser49Gly and Arg389Gly)
are associated with elevated heart rate and/or
hypertension [2,3].
We describe a young patient with unexplained resting
tachycardia and hypertension, in which pathophysio-
logical considerations together with speciﬁc pharma-
cological treatment interventions have led to genetic
analysis and detection of homozygosity for two b1
adrenergic receptor polymorphisms. These polymor-
phisms are associated with a higher risk for hyperten-
sion and tachycardia [2,3] and may explain the
patient’s resistance to b-blocker therapy. The clinical
ﬁndings exactly ﬁt in vitro studies on the cellular level,
where a gain of function could be demonstrated for the
arginine vs glycine allele at position 389 (enhanced
agonist-induced adenylyl cyclase activity [7]) and also
for the serine vs glycine allele at position 49 (reduced
agonist-promoted receptor downregulation [8]).
Among a long list of antihypertensive drug classes, b-
blockers and thiazide diuretics represent the standard
treatment for patients with simple primary hyperten-
sion [9]. Concomitant diseases and side effects are the
major determinants for the choice of other drug classes.
However, with the detection of ACE polymorphisms,
which are frequent among African Americans and
lead to a partial resistance to ACE inhibitor therapy
[4], the importance of genetic factors for the indi-
vidual response to cardiovascular drug treatments has
become evident. In our patient, we found a comparable
situation with resistance to b-blocker therapy due to
Fig. 2. Sequencing results of b1 receptor polymorphism analysis for the index patient and his father and mother. Genomic DNA of the two
main polymorphic loci of the human b1 receptor (Ser49Gly and Arg389Gly) was ampliﬁed by PCR. Products were sequenced according to
standard procedures (see text). (A) Ser49Gly polymorphism: the index patient, his father and his mother were homozygous for serine at
position 49. The important nucleic acid position 145 is shaded. A single peak for A is seen in all three individuals. AGC at this position codes
for serine at position 49. (B) Arg389Gly polymorphism: the index patient and his mother were homozygous for arginine at position 389,
whereas the father was heterozygous for arginine and glycine at this position. The important nucleic acid position 1165 is shaded. A single
peak for C is seen in the index patient and his mother, whereas a double peak for C and G is observed in the father (S stands for C or G in the
sequence analysis, which results in arginine or glycine for the encoded amino acid).
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b1 adrenergic receptor polymorphisms. The clinical
importance of adrenergic receptor polymorphisms has
only been recognized very recently by clinical studies
that demonstrated their association with the incidence
[10] and mortality [11] of congestive heart failure, and
their predictive value for exercise capacity in patients
with heart failure [12].
In conclusion, gain of function of the b1 adrenergic
receptor seems to be detrimental for the heart muscle,
which was experimentally proven by the development
of heart failure in b1 adrenergic receptor transgenic
mice [13]. In contrast, its inhibition by b-blocker
therapy has highly beneﬁcial effects in patients with
heart failure [14]. Given the large number of patients
with arterial hypertension and unexplained systolic
heart failure, screening for adrenergic receptor poly-
morphism might have increasing clinical importance in
the near future.
Teaching point
Adrenergic receptor polymorphisms are an increasingly
recognized cause of unexplained tachycardia, hyperten-
sion and congestive heart failure. These polymorphisms
add to a growing list of genetic factors that determine
an individual’s response to antihypertensive pharma-
cotherapy. It will be a major task in the future to
integrate this information in order to maximally tailor
drug therapy to each individual’s genetic proﬁle. An
optimal effect–side effect relationship should then
result, and our patient may serve as an early example
for this attempt.
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